Arturo Md Molina Sells 30,514 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Stock

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) insider Arturo Md Molina sold 30,514 shares of the business’s stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $55.74, for a total transaction of $1,700,850.36. Following the completion of the sale, the insider now owns 83,892 shares in the company, valued at $4,676,140.08. The trade was a 26.67 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Protagonist Therapeutics Stock Performance

Shares of PTGX opened at $54.78 on Friday. The company’s 50 day moving average price is $39.63 and its 200 day moving average price is $42.24. Protagonist Therapeutics, Inc. has a 52 week low of $24.22 and a 52 week high of $60.60. The company has a market capitalization of $3.36 billion, a PE ratio of 20.59 and a beta of 2.34.

Protagonist Therapeutics (NASDAQ:PTGX) last announced its quarterly earnings data on Friday, February 21st. The company reported $1.98 EPS for the quarter, beating analysts’ consensus estimates of ($0.09) by $2.07. Protagonist Therapeutics had a net margin of 52.76% and a return on equity of 34.68%. The firm had revenue of $170.64 million for the quarter, compared to the consensus estimate of $56.65 million. On average, equities analysts forecast that Protagonist Therapeutics, Inc. will post 2.43 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

PTGX has been the topic of a number of research reports. The Goldman Sachs Group dropped their target price on shares of Protagonist Therapeutics from $43.00 to $38.00 and set a “neutral” rating on the stock in a report on Monday, February 24th. BMO Capital Markets boosted their target price on shares of Protagonist Therapeutics from $62.00 to $72.00 and gave the stock an “outperform” rating in a report on Tuesday. StockNews.com lowered shares of Protagonist Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, December 10th. JMP Securities restated a “market outperform” rating and set a $58.00 price target on shares of Protagonist Therapeutics in a report on Friday, February 7th. Finally, HC Wainwright restated a “buy” rating and set a $54.00 price target on shares of Protagonist Therapeutics in a report on Monday, March 10th. Two equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Protagonist Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $61.22.

Institutional Trading of Protagonist Therapeutics

Several large investors have recently added to or reduced their stakes in the business. Farallon Capital Management LLC grew its position in Protagonist Therapeutics by 1.2% in the fourth quarter. Farallon Capital Management LLC now owns 5,930,006 shares of the company’s stock worth $228,898,000 after acquiring an additional 69,000 shares in the last quarter. RTW Investments LP grew its position in Protagonist Therapeutics by 1.3% in the fourth quarter. RTW Investments LP now owns 5,498,545 shares of the company’s stock worth $212,244,000 after acquiring an additional 72,433 shares in the last quarter. State Street Corp grew its position in Protagonist Therapeutics by 52.9% in the third quarter. State Street Corp now owns 3,183,542 shares of the company’s stock worth $143,259,000 after acquiring an additional 1,101,218 shares in the last quarter. BVF Inc. IL grew its position in Protagonist Therapeutics by 2.7% in the fourth quarter. BVF Inc. IL now owns 1,900,015 shares of the company’s stock worth $73,341,000 after acquiring an additional 49,848 shares in the last quarter. Finally, Pacer Advisors Inc. grew its position in Protagonist Therapeutics by 8.2% in the fourth quarter. Pacer Advisors Inc. now owns 1,876,466 shares of the company’s stock worth $72,432,000 after acquiring an additional 142,376 shares in the last quarter. 98.63% of the stock is owned by institutional investors.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.